AnaptysBio
NASDAQ: ANABSan Diego, US · Founded 2005 · Delaware corporation · 73 employees on LinkedIn · 3 known investors
AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders. It is a publicly traded biotech company running with fewer than ~10 contractors.
Founders & leadership
RH
Robert HoffmaninExecutive
ML
Marco LondeiinExecutive
HS
Hamza SuriainExecutive
DF
Daniel FagainPresident, CEO, and Director
CM
Christopher MurphyCFO
Board
CG
Carol GallagherBoard director
TA
JT
JS
John SchmidBoard director
NL
Nicholas LydonBoard director
HR
Hollings RentonBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$40.8M disclosed across 1 round · 2015
▶$40.8MraisedJul 2015 · 19 investors · BiotechnologyRule 506(b)
▶$40.8MraisedJul 2015 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert HoffmanExecutive Officer
- Carol GallagherDirector
- Marco LondeiExecutive Officer
- Tiba AynechiDirector
- John SchmidDirector
- Nicholas LydonDirector
- Hamza SuriaExecutive Officer, Director
- Hollings RentonDirector
- James TopperDirector
- Offering amount
- $40.8M
- Amount sold
- $40.8M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Fortis Life Sciences25 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Bioworld24 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Aro Biotherapeutics24 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Seeking Alpha24 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with AnaptysBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does AnaptysBio do?
- AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders. It is a publicly traded biotech company running with fewer than ~10 contractors.
- Who are AnaptysBio's investors?
- AnaptysBio's investors include BioBrit, Frazier Life Sciences, Norwest Venture Partners.
- How much funding has AnaptysBio raised?
- AnaptysBio has disclosed $40.8M raised across 1 round.
- Where is AnaptysBio headquartered?
- AnaptysBio is headquartered in San Diego, US.